Patients with ultra-rare diseases worry new FDA rules will leave them without treatment | Medical research

US drug regulators are increasingly focusing on rare approvals and rare diseases, but patients with ultra -comfortable disorders are afraid of cracks, especially considering difficulties for clinical studies.

Elamiprede, a drug, received a narrow suggestion from the US Food and Drug Administration (FDA) independent consultants, but in May, the agency rejected the application of the drug and proposed another potential way for approval.

Patients and defenders are worried about the new rules of who can take the medicine in this process, and whether the drug can be approved before the pharmaceutical company leaves financing.

While underlining the difficulties of progressing in rare and ultra -rare diseases, it also makes sure that treatments are safe and effective.

Hope Filchak, Gainesville, Four and a half years old, who loves swimming in the lakes and pools near his house in Georgia, is one and a half years old. Also deaf and blind, with some functional visions in one eye and hearing with a help in a ear. Hope was born with a rare rare mitochondrial situation called MLS syndrome, only 64 Certified Case As of 2018, in the USA.

MLS syndrome causes a potentially life -threatening heart state called cardiomyopathy, which can make the blood pump less efficient for hope. In February 2024, he began to sleep for about 17 hours a day and his speech began to decline.

A echocardiogram revealed that Hope’s heart function reduces a potentially dangerous area to a dangerous area. Later, he began to take a research medicine for mitochondrial conditions.

“Soon, to be honest, he had much more energy, Car his mother Caroline Filchak said. Most importantly, his heart was stabilized.

Hope’s aunt Anna Bower, her nephew’s nephew, “the quality of life has developed significantly” and soon after, like other children, “running, dancing and playing,” he said.

Elamipretiide, which was first developed in 2004, has a long history. Defenders for patients with Barth syndrome – another mitochondrial condition with approximately 150 known patients – in 2014, the secret biotherapeutics asked for a shepherd during the regulatory process. Stealth submitted his first application to the FDA in 2019, and then passed the four different review departments in the agency.

In October 2024 meeting FDA’s cardiovascular and kidney drugs from the consultation committee patients and doctors spoke about the positive effects of the drug and consultants finally gave 10-6 votes to recommend it.

“Patients and families [advisory committee’s] Don’t confirm as an encouraging sign because FDA almost always follows his advice, Bower Bower said in June. “ But not last month. “

FDA rejected the application in May. Internal FDA Referees remarkable 12 study participants of the drug do not meet the last point in phase 2 trials.

Uz We do not feel that the patient’s voice is looking at evidence in which he heard in the decision, Car Caroline Filchak said, it is difficult to measure the effectiveness of the drug because the disease is rare.

FDA presented a new way of approval, stealth Press release. This process lasts at least eight months, but it may take years. Privacy dismissed 30% of his staff after rejection.

Defenders like Filchak are concerned that the company cannot continue to receive approval.

“If [the FDA] Drag your feet during this process, Stealth will not be able to continue operations. ”

Under the new road, the drug is not available for babies. There is Stealth in question 35 patients around the world take the drug and two -thirds are very sick babies.

At a congress hearing in late June, Republican Representative Earl l “Buddy” Georgia Carter asked Robert F Kennedy JR, the Secretary of the USA of Health and Human Services, about treatments for rare mitochondrial conditions.

Carter talked about two young components, including Hope Filchak. Carter, who promised to follow Kennedy after the hearing, said, “Children need your help in accessing life -saving drugs”.

For now, Hope is supplying a three -month medicine.

“There is no other option for children like hope, Bower Bower said. There are no FDA approved drugs such as Elamipretiide and there are no similar drugs in late development.

Caroline Filchak said that this administration “has a commitment to accelerate therapies for rare diseases. And the FDA’s final decision seems to be compatible with this commitment.

FDA’s commissioner Marty Makary has recently announced that it plans to accelerate approval for certain drugs and companies. He’s also floating The use of machine learning, usually called AI to review applications quickly.

But there is already Four ways Filchak said FDA’s accelerating the review of new drugs and the approval rate is not the point of adhesion for drugs like these.

Elamipretiide, Pennsylvania Perelman Medical Faculty of Medicine Holly Fernandez Lynch, Elamipretiide, is an example for ultra -rare conditions for drug development and clinical evidence.

Fernandez Lynch said, not a poster child of FDA productivity, ”he said.

“But at the same time, ‘Oh my God, we have an incredibly well -working medicine and stand on the way to FDA and why don’t they only use their regulatory flexibility?’

The drug has not yet been approved because Fernandez Lynch added the following because it does not have a predetermined extreme point: “If the evidence does not support approval, the systematic evidence does not benefit, the FDA cannot really approve.”

The biotechnology company is now re -sending data on knee power improvement as part of its new application.

“Of course, these patients need. Of course, they are changing a changed tolerance and uncertainty tolerance for risk, Fern Fernandez Lynch said.

“This is a really destructive part of this. And this doesn’t mean that FDA should approve an unreasonable product, because we don’t know it really works.”

Fernandez Lynch said that the approval of a drug without this evidence could lead to the development of other drugs for the same conditions.

“People, ‘Well, what’s important? These patients have nothing. Just let them try.’ If I were that mother, I would do the same thing, but the FDA should make judgments for the population.

For Caroline Filchak, who works for an oil distribution company, she plans to continue to defend her daughter and other affected children and even took the entire family.

“When you think of having a child, you don’t think you will do it, but you do what you have to do for your children,” he said, his husband said that he took his seven -year -old son Thomas to the October meeting.

“We call him our baby defender. Since that meeting, every night he said his prayers, FDA would pray for saying ‘yes’.”